<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=16631&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="418492" class="table-">
                
                <td>July 7, 2022, 1:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;C01.748.214;C01.748.214;Group 1: a total of 233 participants who received two doses of primary vaccination (1st and 2nd doses) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); a full dose of the AstraZeneca/Fiocruz vaccine and will be followed in the study for six monthsGroup 2: a total of 233 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the AstraZeneca/Fiocruz vaccine; and will be followed up in the study for six monthsGroup 3: a total of 234 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the Pfizer/Wyeth vaccine; and will be followed up in the study for six months&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1: a total of 233 participants who received two doses of primary vaccination (1st and 2nd doses) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); a full dose of the AstraZeneca/Fiocruz vaccine and will be followed in the study for six months&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2: a total of 233 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the AstraZeneca/Fiocruz vaccine; and will be followed up in the study for six months&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 3: a total of 234 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the Pfizer/Wyeth vaccine; and will be followed up in the study for six months&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;full dose, 1st and 2nd doses of the Sinovac&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;half dose, 1st and 2nd doses of the Sinovac&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;half dose, 1st and 2nd doses of the Sinovac&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="417138" class="table-">
                
                <td>June 30, 2022, 4:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1: a total of 233 participants who received two doses of primary vaccination (1st and 2nd doses) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); a full dose of the AstraZeneca/Fiocruz vaccine and will be followed in the study for six monthsGroup 2: a total of 233 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the AstraZeneca/Fiocruz vaccine; and will be followed up in the study for six monthsGroup 3: a total of 234 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the Pfizer/Wyeth vaccine; and will be followed up in the study for six months;C01.748.214;C01.748.214&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1: a total of 233 participants who received two doses of primary vaccination (1st and 2nd doses) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); a full dose of the AstraZeneca/Fiocruz vaccine and will be followed in the study for six months&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2: a total of 233 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the AstraZeneca/Fiocruz vaccine; and will be followed up in the study for six months&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 3: a total of 234 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the Pfizer/Wyeth vaccine; and will be followed up in the study for six months;C01.748.214;C01.748.214&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;half dose&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;half dose&quot;, &quot;treatment_id&quot;: 219, &quot;treatment_name&quot;: &quot;Bnt162&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
July 7, 2022, 1:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "C01.748.214;C01.748.214;Group 1: a total of 233 participants who received two doses of primary vaccination (1st and 2nd doses) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); a full dose of the AstraZeneca/Fiocruz vaccine and will be followed in the study for six monthsGroup 2: a total of 233 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the AstraZeneca/Fiocruz vaccine; and will be followed up in the study for six monthsGroup 3: a total of 234 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the Pfizer/Wyeth vaccine; and will be followed up in the study for six months", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1: a total of 233 participants who received two doses of primary vaccination (1st and 2nd doses) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); a full dose of the AstraZeneca/Fiocruz vaccine and will be followed in the study for six months", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2: a total of 233 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the AstraZeneca/Fiocruz vaccine; and will be followed up in the study for six months", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 3: a total of 234 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the Pfizer/Wyeth vaccine; and will be followed up in the study for six months", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "full dose, 1st and 2nd doses of the Sinovac", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "half dose, 1st and 2nd doses of the Sinovac", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "half dose, 1st and 2nd doses of the Sinovac", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}]
June 30, 2022, 4:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1: a total of 233 participants who received two doses of primary vaccination (1st and 2nd doses) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); a full dose of the AstraZeneca/Fiocruz vaccine and will be followed in the study for six monthsGroup 2: a total of 233 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the AstraZeneca/Fiocruz vaccine; and will be followed up in the study for six monthsGroup 3: a total of 234 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the Pfizer/Wyeth vaccine; and will be followed up in the study for six months;C01.748.214;C01.748.214", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1: a total of 233 participants who received two doses of primary vaccination (1st and 2nd doses) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); a full dose of the AstraZeneca/Fiocruz vaccine and will be followed in the study for six months", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2: a total of 233 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the AstraZeneca/Fiocruz vaccine; and will be followed up in the study for six months", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 3: a total of 234 participants who received two doses of primary vaccination (1st and 2nd dose) of the Sinovac/Butantan vaccine will receive as a booster dose (3rd dose); half a dose of the Pfizer/Wyeth vaccine; and will be followed up in the study for six months;C01.748.214;C01.748.214", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "half dose", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "half dose", "treatment_id": 219, "treatment_name": "Bnt162", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}]